12/4
05:57 am
rvmd
Healthcare stocks are red-hot. Here are 3 picks from a fund manager up 41% this year. [Business Insider]
Low
Report
Healthcare stocks are red-hot. Here are 3 picks from a fund manager up 41% this year. [Business Insider]
11/20
06:02 am
rvmd
Revolution Medicines (NASDAQ:RVMD) was upgraded by analysts at Wolfe Research to a "strong-buy" rating.
Low
Report
Revolution Medicines (NASDAQ:RVMD) was upgraded by analysts at Wolfe Research to a "strong-buy" rating.
11/18
09:00 am
rvmd
Revolution Medicines (NASDAQ:RVMD) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $75.00 price target on the stock.
Low
Report
Revolution Medicines (NASDAQ:RVMD) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $75.00 price target on the stock.
11/17
12:14 pm
rvmd
Hot Picks: Cancer-focused biotech firms gain attention as key clinical results near [BNN Bloomberg (Canada)]
Low
Report
Hot Picks: Cancer-focused biotech firms gain attention as key clinical results near [BNN Bloomberg (Canada)]
11/11
10:58 am
rvmd
Revolution Medicines, Inc. (RVMD) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript [Seeking Alpha]
Low
Report
Revolution Medicines, Inc. (RVMD) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript [Seeking Alpha]
11/8
12:52 pm
rvmd
Revolution Medicines (RVMD): Assessing Valuation After Recent 28% Monthly Share Price Surge [Yahoo! Finance]
Low
Report
Revolution Medicines (RVMD): Assessing Valuation After Recent 28% Monthly Share Price Surge [Yahoo! Finance]
11/6
04:27 pm
rvmd
Revolution Medicines (NASDAQ:RVMD) had its price target raised by analysts at JPMorgan Chase & Co. from $71.00 to $82.00. They now have an "overweight" rating on the stock.
Low
Report
Revolution Medicines (NASDAQ:RVMD) had its price target raised by analysts at JPMorgan Chase & Co. from $71.00 to $82.00. They now have an "overweight" rating on the stock.
11/6
08:40 am
rvmd
Revolution Medicines (NASDAQ:RVMD) had its price target raised by analysts at Needham & Company LLC from $66.00 to $72.00. They now have a "buy" rating on the stock.
Medium
Report
Revolution Medicines (NASDAQ:RVMD) had its price target raised by analysts at Needham & Company LLC from $66.00 to $72.00. They now have a "buy" rating on the stock.
11/6
08:40 am
rvmd
Revolution Medicines (NASDAQ:RVMD) had its price target raised by analysts at Wedbush from $77.00 to $80.00. They now have an "outperform" rating on the stock.
Medium
Report
Revolution Medicines (NASDAQ:RVMD) had its price target raised by analysts at Wedbush from $77.00 to $80.00. They now have an "outperform" rating on the stock.
11/6
08:10 am
rvmd
Revolution Medicines (NASDAQ:RVMD) had its price target raised by analysts at HC Wainwright from $72.00 to $73.00. They now have a "buy" rating on the stock.
Medium
Report
Revolution Medicines (NASDAQ:RVMD) had its price target raised by analysts at HC Wainwright from $72.00 to $73.00. They now have a "buy" rating on the stock.
11/6
12:10 am
rvmd
Revolution Medicines Inc (RVMD) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ... [Yahoo! Finance]
Low
Report
Revolution Medicines Inc (RVMD) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ... [Yahoo! Finance]
11/5
08:46 pm
rvmd
Revolution Medicines, Inc. (RVMD) Q3 2025 Earnings Call Transcript [Seeking Alpha]
Low
Report
Revolution Medicines, Inc. (RVMD) Q3 2025 Earnings Call Transcript [Seeking Alpha]
11/5
08:43 pm
rvmd
Revolution Medicines outlines multiple Phase III trial launches and commercial buildout amid increased R&D investment [Seeking Alpha]
Low
Report
Revolution Medicines outlines multiple Phase III trial launches and commercial buildout amid increased R&D investment [Seeking Alpha]
11/5
04:02 pm
rvmd
Revolution Medicines Reports Third Quarter 2025 Financial Results and Update on Corporate Progress
Medium
Report
Revolution Medicines Reports Third Quarter 2025 Financial Results and Update on Corporate Progress
11/4
04:05 pm
rvmd
Revolution Medicines to Participate in November 2025 Investor Conferences
Low
Report
Revolution Medicines to Participate in November 2025 Investor Conferences
11/3
09:03 am
rvmd
Revolution Medicines (NASDAQ:RVMD) is now covered by analysts at Royal Bank Of Canada. They set an "outperform" rating and a $77.00 price target on the stock.
Low
Report
Revolution Medicines (NASDAQ:RVMD) is now covered by analysts at Royal Bank Of Canada. They set an "outperform" rating and a $77.00 price target on the stock.
10/29
04:05 pm
rvmd
Revolution Medicines to Report Financial Results for Third Quarter 2025 After Market Close on November 5, 2025
Low
Report
Revolution Medicines to Report Financial Results for Third Quarter 2025 After Market Close on November 5, 2025
10/27
08:00 am
rvmd
Revolution Medicines’ RAS(ON) Multi-Selective Inhibitor Daraxonrasib Granted U.S. FDA Orphan Drug Designation in Pancreatic Cancer
Medium
Report
Revolution Medicines’ RAS(ON) Multi-Selective Inhibitor Daraxonrasib Granted U.S. FDA Orphan Drug Designation in Pancreatic Cancer
10/23
06:16 am
rvmd
Revolution Medicines (NASDAQ:RVMD) was upgraded by analysts at Mizuho to a "strong-buy" rating.
Low
Report
Revolution Medicines (NASDAQ:RVMD) was upgraded by analysts at Mizuho to a "strong-buy" rating.
10/22
12:12 pm
rvmd
Revolution Medicines to Present Updated Elironrasib Safety and Efficacy Data in Patients with KRAS G12C Non-Small Cell Lung Cancer Following Treatment with a KRAS(OFF) G12C Inhibitor
Low
Report
Revolution Medicines to Present Updated Elironrasib Safety and Efficacy Data in Patients with KRAS G12C Non-Small Cell Lung Cancer Following Treatment with a KRAS(OFF) G12C Inhibitor
10/21
08:03 am
rvmd
Revolution Medicines (NASDAQ:RVMD) is now covered by analysts at Mizuho. They set an "outperform" rating and a $90.00 price target on the stock.
Low
Report
Revolution Medicines (NASDAQ:RVMD) is now covered by analysts at Mizuho. They set an "outperform" rating and a $90.00 price target on the stock.
10/19
03:31 am
rvmd
Jim Cramer Says Revolution Medicines “Is a Speculative Situation” [Yahoo! Finance]
Low
Report
Jim Cramer Says Revolution Medicines “Is a Speculative Situation” [Yahoo! Finance]
10/17
12:08 pm
rvmd
Revolution Medicines (NASDAQ:RVMD) was given a new $80.00 price target on by analysts at National Bankshares, Inc..
Low
Report
Revolution Medicines (NASDAQ:RVMD) was given a new $80.00 price target on by analysts at National Bankshares, Inc..
10/17
10:03 am
rvmd
Revolution Medicines (NASDAQ:RVMD) was given a new $76.00 price target on by analysts at Raymond James Financial, Inc.. They now have a "strong-buy" rating on the stock.
Low
Report
Revolution Medicines (NASDAQ:RVMD) was given a new $76.00 price target on by analysts at Raymond James Financial, Inc.. They now have a "strong-buy" rating on the stock.
10/17
08:35 am
rvmd
Revolution Medicines (NASDAQ:RVMD) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $77.00 price target on the stock.
Low
Report
Revolution Medicines (NASDAQ:RVMD) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $77.00 price target on the stock.